G. Hoel

发表

Rapid efficacy of the highly selective α(1A)-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies.

L. Hill, L. Marks, W. Volinn, 2009, The Journal of urology.

Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies.

L. Hill, L. Marks, W. Volinn, 2009, The Journal of urology.

Pharmacokinetics of Oxybutynin Chloride Topical Gel

R. Dmochowski, D. Newman, P. Sand, 2011, Clinical drug investigation.

Efficacy and safety of oxybutynin chloride topical gel for women with overactive bladder syndrome.

G. Davila, V. Lucente, P. Sand, 2012, American journal of obstetrics and gynecology.

Effect of silodosin on specific urinary symptoms associated with benign prostatic hyperplasia: analysis of international prostate symptom scores in 2 phase III clinical studies

L. Hill, L. Marks, W. Volinn, 2010, Open access journal of urology.

Silodosin for men with chronic prostatitis/chronic pelvic pain syndrome: results of a phase II multicenter, double-blind, placebo controlled study.

H. Lepor, L. Hill, J. Nickel, 2011, The Journal of urology.

Immunologic localization and kinetic characterization of a Na+/Ca2+ exchanger in neuronal and non-neuronal cells

M. Michaelis, M. Hurlbert, W. Kwong, 1994, Brain Research.

Lack of pharmacodynamic interaction of silodosin, a highly selective alpha1a-adrenoceptor antagonist, with the phosphodiesterase-5 inhibitors sildenafil and tadalafil in healthy men.

L. Hill, S. Macdiarmid, W. Volinn, 2010, Urology.

Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study.

R. Dmochowski, D. Staskin, S. Macdiarmid, 2009, The Journal of urology.

Efficacy and safety of transdermal and oral oxybutynin in children with neurogenic detrusor overactivity.

D. Coplen, P. Cartwright, B. Kogan, 2009, The Journal of urology.

Silodosin in the treatment of the signs and symptoms of benign prostatic hyperplasia: a 9-month, open-label extension study.

L. Hill, L. Marks, W. Volinn, 2009, Urology.

Effects of the Selective α1A‐Adrenoceptor Antagonist Silodosin on ECGs of Healthy Men in a Randomized, Double‐Blind, Placebo‐ and Moxifloxacin‐Controlled Study

H. Lepor, L. Hill, J. Morganroth, 2010, Clinical pharmacology and therapeutics.

Characterization of Na+−Ca2+ exchange activity in plasma membrane vesicles from postmortem human brain

J. Kleinman, W. Freed, M. Michaelis, 1990, Neurochemical Research.

Effect of baseline symptom severity on continence improvement mediated by oxybutynin chloride topical gel

S. Macdiarmid, P. Sand, G. Hoel, 2011, Open access journal of urology.

Effects of Oxybutynin Chloride Topical Gel on Health-Related Quality of Life in Adults with Overactive Bladder: A Randomized, Double-Blind, Placebo-Controlled Study

R. Dmochowski, P. Hanno, D. Newman, 2010 .

Quality of Life in a Randomized, Double-Blind, Placebo-Controlled Study of Oxybutynin Chloride Topical Gel Treatment of Patients With Overactive Bladder

P. Hanno, D. Rudy, G. Hoel, 2009 .

Efficacy and safety of transdermal and oral oxybutynin in children with neurogenic detrusor overactivity.

D. Coplen, P. Cartwright, B. Kogan, 2009, The Journal of urology.